epirubicin - CISMeF

Preferred Label : epirubicin;

MeSH definition : An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.;

MeSH synonym : 4'-epi-dxr; 4' epi dxr; 4'-epi-doxorubicin; 4' epi adriamycin; 4' epidoxorubicin; 4'-epidoxorubicin; 4' epi doxorubicin; 4'-epi-adriamycin; 4'-epiadriamycin; 4' epiadriamycin;

CISMeF synonym : pharmacia brand of epirubicin hydrochloride; 56390-09-1 (Epirubicin hydrochloride); cell pharm brand of epirubicin; lemery brand of epirubicin hydrochloride; kenfarma brand of epirubicin hydrochloride; pfizer brand of epirubicin hydrochloride;

MeSH hyponym : epilem; NSC-256942; IMI-28; epirubicin hydrochloride; farmorubicina; ellence; EPI-cell; EPI cell; EPIcell; IMI 28; IMI28; NSC 256942; NSC256942; Pharmorubicin; Farmorubicine; Farmorubicin; Hydrochloride, Epirubicin;

MeSH CAS label : 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-;

MeSH Related Number : epirubicin hydrochloride; 56390-09-1 (HCl); 56420-45-2 (Epirubicin); 22966TX7J5;

Registry Number MeSH : 56420-45-2;

Related CAS MeSH : 22966TX7J5 (Epirubicin hydrochloride);

Wikipedia link : https://en.wikipedia.org/wiki/Epirubicin;

Is substance : O;

UNII : 3Z8479ZZ5X;

InChIKey : AOJJSUZBOXZQNB-VTZDEGQISA-N;

Details

Origin ID

D015251;

UMLS CUI

C0014582;

ATC code(s)
- epirubicin [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Epirubicin adverse reaction (disorder) [SNOMED CT concept]
- Epirubicin poisoning (disorder) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Epirubicin [ICD-11 Extension code]
- Epirubicin [NCIt concept]
- Epirubicin (substance) [SNOMED CT concept]
Pharmacological action(s)
- antibiotics, antineoplastic [MeSH Descriptor]
- enzyme inhibitors [MeSH Descriptor]
- topoisomerase II inhibitors [MeSH Descriptor]
Record concept(s)
- EPI-cell [MeSH concept]
- IMI-28 [MeSH concept]
- NSC-256942 [MeSH concept]
- ellence [MeSH concept]
- epilem [MeSH concept]
- epirubicin [MeSH concept]
- epirubicin hydrochloride [MeSH concept]
- farmorubicina [MeSH concept]
Related MeSH Supplementary Concept(s)
- 13-dihydro-4'-epidoxorubicin [MeSH Supplementary Concept]
- 3'-azido-epirubicin [MeSH Supplementary Concept]
- 3'-deamino-3'-hydroxydoxorubicin [MeSH Supplementary Concept]
- CCA protocol [MeSH Supplementary Concept]
- CE protocol II [MeSH Supplementary Concept]
- CEE protocol [MeSH Supplementary Concept]
- CEF regimen [MeSH Supplementary Concept]
- CEFT protocol [MeSH Supplementary Concept]
- CEO-PE protocol [MeSH Supplementary Concept]
- CEOP protocol 1 [MeSH Supplementary Concept]
- CEOP protocol 2 [MeSH Supplementary Concept]
- CEOP-B protocol [MeSH Supplementary Concept]
- CEOP-IMVP-Dexa regimen [MeSH Supplementary Concept]
- CEOP-MB protocol [MeSH Supplementary Concept]
- CEP combination [MeSH Supplementary Concept]
- CEP regimen [MeSH Supplementary Concept]
- CEV protocol [MeSH Supplementary Concept]
- CEVBP protocol [MeSH Supplementary Concept]
- CEVP protocol [MeSH Supplementary Concept]
- CYVEDIC protocol [MeSH Supplementary Concept]
- Carbo-MVE protocol [MeSH Supplementary Concept]
- EAP-II protocol [MeSH Supplementary Concept]
- EBV protocol [MeSH Supplementary Concept]
- EBVD protocol [MeSH Supplementary Concept]
- EBVP protocol [MeSH Supplementary Concept]
- ECT chemotherapy protocol [MeSH Supplementary Concept]
- ECarboX protocol [MeSH Supplementary Concept]
- EDP protocol [MeSH Supplementary Concept]
- EEP protocol [MeSH Supplementary Concept]
- EEPFL protocol [MeSH Supplementary Concept]
- EID protocol [MeSH Supplementary Concept]
- ELFE regimen [MeSH Supplementary Concept]
- EMB protocol [MeSH Supplementary Concept]
- ET protocol [MeSH Supplementary Concept]
- EVDAC regimen [MeSH Supplementary Concept]
- EVM protocol [MeSH Supplementary Concept]
- EVP protocol [MeSH Supplementary Concept]
- FDE protocol [MeSH Supplementary Concept]
- FEC protocol [MeSH Supplementary Concept]
- FEM protocol [MeSH Supplementary Concept]
- FEMTX protocol [MeSH Supplementary Concept]
- FEMTX-P protocol [MeSH Supplementary Concept]
- FEN protocol [MeSH Supplementary Concept]
- FLEC protocol [MeSH Supplementary Concept]
- FLEP protocol [MeSH Supplementary Concept]
- FPEPIR regimen [MeSH Supplementary Concept]
- GET protocol [MeSH Supplementary Concept]
- IEV protocol [MeSH Supplementary Concept]
- IEVM protocol [MeSH Supplementary Concept]
- M-VEC protocol [MeSH Supplementary Concept]
- MEC protocol 2 [MeSH Supplementary Concept]
- MEP regimen [MeSH Supplementary Concept]
- MPEpiE protocol [MeSH Supplementary Concept]
- MPEpiV protocol [MeSH Supplementary Concept]
- N-(3-pyridylmethyl)dihydroepidoxorubicin [MeSH Supplementary Concept]
- N-(3-pyridylmethyl)epidoxorubicin [MeSH Supplementary Concept]
- NC 6300 [MeSH Supplementary Concept]
- OEPP protocol [MeSH Supplementary Concept]
- OPP-EBV-CAD regimen [MeSH Supplementary Concept]
- P-DOCE protocol [MeSH Supplementary Concept]
- P-VEBEC protocol [MeSH Supplementary Concept]
- PE regimen [MeSH Supplementary Concept]
- PELF protocol 2 [MeSH Supplementary Concept]
- PET regimen [MeSH Supplementary Concept]
- PEV-B protocol [MeSH Supplementary Concept]
- ProMECE-CytaBOM protocol [MeSH Supplementary Concept]
- VEBEP regimen [MeSH Supplementary Concept]
- VEEP regimen [MeSH Supplementary Concept]
- VEMP protocol 2 [MeSH Supplementary Concept]
- VIC-E protocol [MeSH Supplementary Concept]
- VIE protocol [MeSH Supplementary Concept]
- VIP-E protocol [MeSH Supplementary Concept]
- epidoxoform [MeSH Supplementary Concept]
- epidoxorubicin glucuronide [MeSH Supplementary Concept]
- epirubicin-copper(II) complex [MeSH Supplementary Concept]
- m-BECOD protocol [MeSH Supplementary Concept]
- nitric oxide-pegylated epirubicin [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Epirubicin [ICD-11 Extension code]
- Epirubicin [NCIt concept]
- Epirubicin (substance) [SNOMED CT concept]
- Product containing epirubicin (medicinal product) [SNOMED CT concept]
- epirubicin [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients